GTx Closer To Filing NDA For Acapodene With Promising Phase III Results
Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.
Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.